Morphotek Executive, Rodney Dausch, Named Small Company CFO of the Year in the Greater Philadelphia Region
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that Rodney Dausch, Vice President and Chief Financial Officer (CFO), received the Philadelphia Business Journal/Drexel University’s LeBow College of Business Small Company CFO of the Year Award. According to the Journal, the award recognizes outstanding CFOs who strategically lead their company’s growth, profits and marketing position in addition to maintain its reputation, ethics and accountability to its shareholders and community. Dausch was selected by an independent panel of judges and the award was presented at a luncheon event at the Sheraton City Center Hotel in Philadelphia on July 17, 2008.
The Philadelphia Business Journal and Drexel University’s LeBow College of Business strive to honor business executives in the Greater Philadelphia region who have demonstrated excellence in such areas as innovation, financial performance, and personal commitment to their businesses and communities.
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology. The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit www.morphotek.com.
About Eisai Corporation of North America
Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three areas of therapeutic focus: Integrative neuroscience including neurology and psychiatric medicines; gastrointestinal disorders; and integrative oncology including oncotherapy and supportive-care treatments. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 10,000 people worldwide. For more information, please visit www.eisai.co.jp.